Antipsychotic Treatment Failure? - Clozapine is "the only rational alternative"¹

NIMH Collaborative Study "CATIE" (Clinical Antipsychotic Trials for Interventions Effectiveness)

The US National Institute of Mental Health's CATIE comparative study of antipsychotic medicines for patients with treatment-resistant schizophrenia (Phase 2) revealed that clozapine is substantially more effective than any other medicine tested². Clozapine was proven superior to olanzapine, quetiapine and risperidone in both efficacy (rating scale improvements) and effectiveness (duration of monotherapy). According to Carol Tamminga, MD, editor of the American Journal of Psychiatry, when faced with antipsychotic treatment failure, "clozapine is the only rational alternative".

FazaClo. The CATIE-2 authors concluded: "Given the superior effectiveness of clozapine relative to all other antipsychotics, efforts to develop models of service delivery that would encourage its greater use are warranted." Azur Pharma is committed to providing support services consistent with the CATIE-2 recommendations for expanded use of clozapine through such improved service delivery concepts as the development and expansion of clozapine clinics. With FazaClo brand of clozapine, therapeutic outcomes may be enhanced because Azur Pharma provides unique services to help doctors manage a greater number of patients safely.

Patient Safety Support Services Unique to FazaClo. When doctors prescribe FazaClo - the more convenient orally disintegrating tablet form of clozapine - Azur Pharma provides the possibility of unique safety support services. These include a 24/7 medical hotline and a nationwide team of FazaClo Systems Consultants - health professionals specially trained to organize, expedite and maintain the requisite blood test results designed to enhance patient safety³.

How FazaClo May Improve the CATIE Outcomes. Taking the CATIE data as the baseline, one can envision even better results with FazaClo orally disintegrating tablets, because Azur Pharma gives doctors and clinics help they may need to optimize treatment safety. Clinical study data show that 8 out of 10 patients crossed-over from an older form of clozapine say they like taking FazaClo orally disintegrating clozapine formulation⁴. And, when patients like taking their medication, they are much more likely to continue treatment.

For more information follow these links:

• NIMH CATIE Study

• NIMH CATIE FAQs